Hexokinase 2 expression in apical enterocytes correlates with inflammation severity in patients with inflammatory bowel disease.
HK2
Hexokinase
Human biopsies
Inflammation
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
07
06
2024
accepted:
16
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Inflammation is characterized by a metabolic switch promoting glycolysis and lactate production. Hexokinases (HK) catalyze the first reaction of glycolysis and inhibition of epithelial HK2 protected from colitis in mice. HK2 expression has been described as elevated in patients with intestinal inflammation; however, there is conflicting data from few cohorts especially with severely inflamed individuals; thus, systematic studies linking disease activity with HK2 levels are needed. We examined the relationship between HK2 expression and inflammation severity using bulk transcriptome data derived from the mucosa of thoroughly phenotyped inflammatory bowel disease (IBD) patients of two independent cohorts including both subtypes Crohn's disease (CD) and ulcerative colitis (UC). Publicly available single-cell RNA sequencing data were analyzed, and immunofluorescence staining on colonic biopsies of unrelated patients with intestinal inflammation was performed to confirm the RNA-based findings on cellular and protein level. HK2 expression gradually increased from mild to intermediate inflammation, yet strongly declined at high inflammation scores. Expression of epithelial marker genes also declined at high inflammation scores, whereas that of candidate immune marker genes increased, indicating a cellular remodeling of the mucosa during inflammation with an infiltration of HK2-negative immune cells and a loss of terminal differentiated epithelial cells in the apical epithelium-the main site of HK2 expression. Normalizing for the enterocyte loss clearly identified epithelial HK2 expression as gradually increasing with disease activity and remaining elevated at high inflammation scores. HK2 protein expression was mostly restricted to brush border enterocytes, and these cells along with HK2 levels vanished with increasing disease severity. Our findings clearly define dysregulated epithelial HK2 expression as an indicator of disease activity in intestinal inflammation and suggest targeted HK2-inhibition as a potential therapeutic avenue.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation is characterized by a metabolic switch promoting glycolysis and lactate production. Hexokinases (HK) catalyze the first reaction of glycolysis and inhibition of epithelial HK2 protected from colitis in mice. HK2 expression has been described as elevated in patients with intestinal inflammation; however, there is conflicting data from few cohorts especially with severely inflamed individuals; thus, systematic studies linking disease activity with HK2 levels are needed.
METHODS
METHODS
We examined the relationship between HK2 expression and inflammation severity using bulk transcriptome data derived from the mucosa of thoroughly phenotyped inflammatory bowel disease (IBD) patients of two independent cohorts including both subtypes Crohn's disease (CD) and ulcerative colitis (UC). Publicly available single-cell RNA sequencing data were analyzed, and immunofluorescence staining on colonic biopsies of unrelated patients with intestinal inflammation was performed to confirm the RNA-based findings on cellular and protein level.
RESULTS
RESULTS
HK2 expression gradually increased from mild to intermediate inflammation, yet strongly declined at high inflammation scores. Expression of epithelial marker genes also declined at high inflammation scores, whereas that of candidate immune marker genes increased, indicating a cellular remodeling of the mucosa during inflammation with an infiltration of HK2-negative immune cells and a loss of terminal differentiated epithelial cells in the apical epithelium-the main site of HK2 expression. Normalizing for the enterocyte loss clearly identified epithelial HK2 expression as gradually increasing with disease activity and remaining elevated at high inflammation scores. HK2 protein expression was mostly restricted to brush border enterocytes, and these cells along with HK2 levels vanished with increasing disease severity.
CONCLUSIONS
CONCLUSIONS
Our findings clearly define dysregulated epithelial HK2 expression as an indicator of disease activity in intestinal inflammation and suggest targeted HK2-inhibition as a potential therapeutic avenue.
Identifiants
pubmed: 39444028
doi: 10.1186/s12916-024-03710-7
pii: 10.1186/s12916-024-03710-7
doi:
Substances chimiques
Hexokinase
EC 2.7.1.1
HK2 protein, human
EC 2.7.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
490Informations de copyright
© 2024. The Author(s).
Références
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.
pubmed: 33033392
doi: 10.1038/s41575-020-00360-x
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.
pubmed: 26323879
doi: 10.1038/nrgastro.2015.150
Rath E, Haller D. Intestinal epithelial cell metabolism at the interface of microbial dysbiosis and tissue injury. Mucosal Immunol. 2022;15:595–604.
pubmed: 35534699
pmcid: 9259489
doi: 10.1038/s41385-022-00514-x
Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol. 2017;13:267–79.
pubmed: 28331208
doi: 10.1038/nrrheum.2017.37
Soto-Heredero G, Gómez de las Heras MM, Gabandé-Rodríguez E, Oller J, Mittelbrunn M. Glycolysis – a key player in the inflammatory response. FEBS J. 2020;287:3350–69.
pubmed: 32255251
pmcid: 7496292
doi: 10.1111/febs.15327
Hinrichsen F, Hamm J, Westermann M, Schröder L, Shima K, Mishra N, et al. Microbial regulation of hexokinase 2 links mitochondrial metabolism and cell death in colitis. Cell Metab. 2021;33:2355–2366.e8.
pubmed: 34847376
doi: 10.1016/j.cmet.2021.11.004
Peters LA, Perrigoue J, Mortha A, Iuga A, Song W-M, Neiman EM, et al. A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat Genet. 2017;49:1437–49.
pubmed: 28892060
pmcid: 5660607
doi: 10.1038/ng.3947
Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68:25–39. https://identifiers.org/geo:GSE191328 . GEO.
pubmed: 29730603
doi: 10.1136/gutjnl-2018-316023
Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160:2354–2366.e11. https://identifiers.org/geo:GSE171770 . GEO.
pubmed: 33667488
doi: 10.1053/j.gastro.2021.02.062
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. The Lancet. 1980;315:514.
doi: 10.1016/S0140-6736(80)92767-1
R Core Team. R: a language and environment for statistical computing [Internet]. Vienna: R Foundation for Statistical Computing; 2022. Available from: https://www.R-project.org/ .
Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1–48.
doi: 10.18637/jss.v067.i01
Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1–26.
doi: 10.18637/jss.v082.i13
Fox J, Weisberg S. An R companion to applied regression. 3rd ed. Thousand Oaks CA: Sage; 2019.
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016.
doi: 10.1007/978-3-319-24277-4
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Wang X, Park J, Susztak K, Zhang NR, Li M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat Commun. 2019;10:380.
pubmed: 30670690
pmcid: 6342984
doi: 10.1038/s41467-018-08023-x
Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178:714–730.e22. https://singlecell.broadinstitute.org/single_cell/study/SCP259/intra-and-inter-cellular-rewiring-of-the-human-colon-during-ulcerative-colitis . Single Cell Portal.
pubmed: 31348891
pmcid: 6662628
doi: 10.1016/j.cell.2019.06.029
Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573–3587.e29.
pubmed: 34062119
pmcid: 8238499
doi: 10.1016/j.cell.2021.04.048
Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66:43–9.
pubmed: 26464414
doi: 10.1136/gutjnl-2015-310187
Marigorta UM, Denson LA, Hyams JS, Mondal K, Prince J, Walters TD, et al. Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn’s disease. Nat Genet. 2017;49:1517–21.
pubmed: 28805827
pmcid: 5745037
doi: 10.1038/ng.3936
Haberman Y, Tickle TL, Dexheimer PJ, Kim M-O, Tang D, Karns R, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014;124:3617–33.
pubmed: 25003194
pmcid: 4109533
doi: 10.1172/JCI75436
Quraishi MN, Acharjee A, Beggs AD, Horniblow R, Tselepis C, Gkoutos G, et al. A pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways. J Crohns Colitis. 2020;14:935–47.
pubmed: 32016358
pmcid: 7392170
doi: 10.1093/ecco-jcc/jjaa021
Sommer F, Nookaew I, Sommer N, Fogelstrand P, Bäckhed F. Site-specific programming of the host epithelial transcriptome by the gut microbiota. Genome Biol. 2015;16:62.
pubmed: 25887251
pmcid: 4404278
doi: 10.1186/s13059-015-0614-4
The Tabula Muris Consortium, Overall coordination, Logistical coordination, Organ collection and processing, Library preparation and sequencing, Computational data analysis, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature. 2018;562:367–72.
doi: 10.1038/s41586-018-0590-4
Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:1–16.
doi: 10.1155/2019/7247238
Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med. 2012;209:1595–609.
pubmed: 22891275
pmcid: 3428945
doi: 10.1084/jem.20111453
Chotikatum S, Naim HY, El-Najjar N. Inflammation induced ER stress affects absorptive intestinal epithelial cells function and integrity. Int Immunopharmacol. 2018;55:336–44.
pubmed: 29324356
doi: 10.1016/j.intimp.2017.12.016
Lin Y, Li B, Yang X, Liu T, Shi T, Deng B, et al. Non-hematopoietic STAT6 induces epithelial tight junction dysfunction and promotes intestinal inflammation and tumorigenesis. Mucosal Immunol. 2019;12:1304–15.
pubmed: 31534167
doi: 10.1038/s41385-019-0204-y
He L, Liu T, Shi Y, Tian F, Hu H, Deb DK, et al. Gut epithelial vitamin D receptor regulates microbiota-dependent mucosal inflammation by suppressing intestinal epithelial cell apoptosis. Endocrinology. 2018;159:967–79.
pubmed: 29228157
doi: 10.1210/en.2017-00748
Moor AE, Harnik Y, Ben-Moshe S, Massasa EE, Rozenberg M, Eilam R, et al. Spatial reconstruction of single enterocytes uncovers broad zonation along the intestinal villus axis. Cell. 2018;175:1156–1167.e15.
pubmed: 30270040
doi: 10.1016/j.cell.2018.08.063
Wei X, Tan X, Chen Q, Jiang Y, Wu G, Ma X, et al. Extensive jejunal injury is repaired by migration and transdifferentiation of ileal enterocytes in zebrafish. Cell Rep. 2023;42: 112660.
pubmed: 37342912
doi: 10.1016/j.celrep.2023.112660
López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1:303–14.
pubmed: 20049734
pmcid: 3378143
doi: 10.1002/emmm.200900043
Roediger WEW. The colonic epithelium in ulcerative colitis: an energy-deficiency disease. The Lancet. 1980;316:712–5.
doi: 10.1016/S0140-6736(80)91934-0
Khaloian S, Rath E, Hammoudi N, Gleisinger E, Blutke A, Giesbertz P, et al. Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence. Gut. 2020;69:1939–51.
pubmed: 32111634
doi: 10.1136/gutjnl-2019-319514
Jackson DN, Panopoulos M, Neumann WL, Turner K, Cantarel BL, Thompson-Snipes L, et al. Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis. Gut. 2020;69:1928–38.
pubmed: 32111635
doi: 10.1136/gutjnl-2019-319523
Berger E, Rath E, Yuan D, Waldschmitt N, Khaloian S, Allgäuer M, et al. Mitochondrial function controls intestinal epithelial stemness and proliferation. Nat Commun. 2016;7:13171.
pubmed: 27786175
pmcid: 5080445
doi: 10.1038/ncomms13171
Ho G-T, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, et al. MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol. 2018;11:120–30.
pubmed: 28401939
doi: 10.1038/mi.2017.31
Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021;593:238–43.
pubmed: 33828297
pmcid: 9153265
doi: 10.1038/s41586-021-03446-x
Lin Z, Nelson L, Franke A, Poritz L, Li T-Y, Wu R, et al. OCTN1 variant L503F is associated with familial and sporadic inflammatory bowel disease. J Crohns Colitis. 2010;4:132–8.
pubmed: 21122496
doi: 10.1016/j.crohns.2009.09.003
Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–11.
pubmed: 17200669
doi: 10.1038/ng1954
Saxena A, Lopes F, Poon KKH, McKay DM. Absence of the NOD2 protein renders epithelia more susceptible to barrier dysfunction due to mitochondrial dysfunction. Am J Physiol-Gastrointest Liver Physiol. 2017;313:G26–38.
pubmed: 28450277
doi: 10.1152/ajpgi.00070.2017
Santhanam S, Rajamanickam S, Motamarry A, Ramakrishna BS, Amirtharaj JG, Ramachandran A, et al. Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis: Inflamm Bowel Dis. 2012;18:2158–68.
pubmed: 22374887
Sifroni KG, Damiani CR, Stoffel C, Cardoso MR, Ferreira GK, Jeremias IC, et al. Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitis. Mol Cell Biochem. 2010;342:111–5.
pubmed: 20440543
doi: 10.1007/s11010-010-0474-x
Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell. 2016;166:624–36.
pubmed: 27374331
pmcid: 5534359
doi: 10.1016/j.cell.2016.05.076
Baik SH, Ramanujan VK, Becker C, Fett S, Underhill DM, Wolf AJ. Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation. Sci Immunol. 2023;8:eade7652.
pubmed: 37327321
pmcid: 10360408
doi: 10.1126/sciimmunol.ade7652
Fueger PT, Heikkinen S, Bracy DP, Malabanan CM, Pencek RR, Laakso M, et al. Hexokinase II partial knockout impairs exercise-stimulated glucose uptake in oxidative muscles of mice. Am J Physiol-Endocrinol Metab. 2003;285:E958–63.
pubmed: 12865258
doi: 10.1152/ajpendo.00190.2003
Smeele KMA, Southworth R, Wu R, Xie C, Nederlof R, Warley A, et al. Disruption of hexokinase II–mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis. Circ Res. 2011;108:1165–9.
pubmed: 21527739
doi: 10.1161/CIRCRESAHA.111.244962
Wu R, Wyatt E, Chawla K, Tran M, Ghanefar M, Laakso M, et al. Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med. 2012;4:633–46.
pubmed: 22517678
pmcid: 3407950
doi: 10.1002/emmm.201200240
Di Sabatino A, Cazzola P, Ciccocioppo R, Morera R, Biancheri P, Rovedatti L, et al. Efficacy of butyrate in the treatment of mild to moderate Crohn’s disease. Dig Liver Dis Suppl. 2007;1:31–5.
Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005;22:789–94.
pubmed: 16225487
doi: 10.1111/j.1365-2036.2005.02639.x
Scheppach W, Sommer H, Kirchner T, Paganelli G-M, Bartram P, Christl S, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103:51–6.
pubmed: 1612357
doi: 10.1016/0016-5085(92)91094-K
Theismann E-M, Keppler JK, Knipp J-R, Fangmann D, Appel E, Gorb SN, et al. Adjustment of triple shellac coating for precise release of bioactive substances with different physico-chemical properties in the ileocolonic region. Int J Pharm. 2019;564:472–84.
pubmed: 30991131
doi: 10.1016/j.ijpharm.2019.04.039
Zheng M, Wu C, Yang K, Yang Y, Liu Y, Gao S, et al. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. Pharmacol Res. 2021;164: 105367.
pubmed: 33307221
doi: 10.1016/j.phrs.2020.105367
Shi R, Pan P, Lv R, Ma C, Wu E, Guo R, et al. High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots–assisted LDI mass spectrometry. Sci Adv. 2022;8:eabl4923.
pubmed: 35171681
pmcid: 10921956
doi: 10.1126/sciadv.abl4923